13-ID-197: A Phase III Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio

Grants and Contracts Details

StatusFinished
Effective start/end date3/5/142/28/17

Funding

  • PaxVax Incorporated: $159,327.00